WEBSITE BSE:524164 NSE : IOL CHEM PH 10 May, 16:01
Market Cap ₹2238 Cr.
Stock P/E 13.0
P/B 1.4
Current Price ₹381.2
Book Value ₹ 274.7
Face Value 10
52W High ₹535.6
Dividend Yield 1.05%
52W Low ₹ 350.3
IOL Chemicals and Pharmaceuticals Ltd is a pharmaceutical organization. The Company is engaged in production and promoting of organic chemical substances and bulk drugs. It caters to each domestic and worldwide markets. It operates thru 2 segments: Chemicals and Drugs. The Chemicals section produces and sells acetic anhydride, acetyl chloride, mono chloro acetic acid and iso butyl benzene. The Drugs segment produces and sells numerous APIs, consisting of ibuprofen and metformin. Its operations include Bulk Drugs APIs and speciality business natural chemical compounds. Its APIs department includes production of Bulk Drugs, along with anti inflammatory and anti-diabetic. Its Speciality Industrial Organic Chemicals division produces ethyl acetate from organic alcohol for use in various end products in markets, together with flexible packaging, prescribed drugs, meals processing, pesticides and paint industries. Its manufacturing facility is in Barnala, Punjab.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 572 | 565 | 541 | 523 | 587 | 563 | 545 | 520 |
| Other Income | 0 | 7 | 5 | 5 | 7 | 9 | 7 | 7 | 8 |
| Total Income | 0 | 579 | 570 | 546 | 530 | 596 | 570 | 552 | 529 |
| Total Expenditure | 0 | 527 | 509 | 510 | 481 | 492 | 491 | 481 | 476 |
| Operating Profit | 0 | 52 | 61 | 37 | 49 | 104 | 80 | 71 | 53 |
| Interest | 0 | 2 | 3 | 4 | 5 | 5 | 4 | 4 | 4 |
| Depreciation | 0 | 11 | 11 | 11 | 12 | 12 | 14 | 16 | 16 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 39 | 47 | 22 | 33 | 87 | 61 | 51 | 32 |
| Provision for Tax | 0 | 9 | 12 | 6 | 9 | 22 | 15 | 13 | 9 |
| Profit After Tax | 0 | 30 | 35 | 16 | 24 | 65 | 46 | 38 | 23 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 30 | 35 | 16 | 24 | 65 | 46 | 38 | 23 |
| Adjusted Earnings Per Share | 0 | 5.1 | 5.9 | 2.7 | 4.1 | 11 | 7.8 | 6.5 | 3.9 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|
| Net Sales | 2184 | 2217 | 2215 |
| Other Income | 32 | 26 | 31 |
| Total Income | 2216 | 2243 | 2247 |
| Total Expenditure | 1926 | 1991 | 1940 |
| Operating Profit | 290 | 251 | 308 |
| Interest | 8 | 16 | 17 |
| Depreciation | 43 | 46 | 58 |
| Exceptional Income / Expenses | -14 | 0 | 0 |
| Profit Before Tax | 225 | 189 | 231 |
| Provision for Tax | 57 | 50 | 59 |
| Profit After Tax | 168 | 139 | 172 |
| Adjustments | 0 | 0 | 0 |
| Profit After Adjustments | 168 | 139 | 172 |
| Adjusted Earnings Per Share | 28.6 | 23.7 | 29.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 2% | 0% | 0% | 0% |
| Operating Profit CAGR | -13% | 0% | 0% | 0% |
| PAT CAGR | -17% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -5% | -17% | 16% | 31% |
| ROE Average | 10% | 11% | 11% | 11% |
| ROCE Average | 14% | 15% | 15% | 15% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 |
|---|---|---|
| Shareholder's Funds | 1392 | 1508 |
| Minority's Interest | 0 | 0 |
| Borrowings | 0 | 0 |
| Other Non-Current Liabilities | 57 | 58 |
| Total Current Liabilities | 575 | 503 |
| Total Liabilities | 2024 | 2068 |
| Fixed Assets | 561 | 752 |
| Other Non-Current Assets | 321 | 350 |
| Total Current Assets | 1143 | 967 |
| Total Assets | 2024 | 2068 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 |
|---|---|---|
| Opening Cash & Cash Equivalents | 32 | 3 |
| Cash Flow from Operating Activities | 93 | 122 |
| Cash Flow from Investing Activities | -121 | -120 |
| Cash Flow from Financing Activities | -2 | -4 |
| Net Cash Inflow / Outflow | -29 | -2 |
| Closing Cash & Cash Equivalent | 3 | 1 |
| # | Mar 2022 | Mar 2023 |
|---|---|---|
| Earnings Per Share (Rs) | 28.56 | 23.7 |
| CEPS(Rs) | 35.93 | 31.56 |
| DPS(Rs) | 4 | 4 |
| Book NAV/Share(Rs) | 237.15 | 256.81 |
| Core EBITDA Margin(%) | 11.83 | 10.18 |
| EBIT Margin(%) | 10.67 | 9.25 |
| Pre Tax Margin(%) | 10.3 | 8.51 |
| PAT Margin (%) | 7.68 | 6.28 |
| Cash Profit Margin (%) | 9.66 | 8.36 |
| ROA(%) | 8.28 | 6.8 |
| ROE(%) | 12.04 | 9.6 |
| ROCE(%) | 16.25 | 13.57 |
| Receivable days | 78.51 | 80.26 |
| Inventory Days | 68.5 | 60.53 |
| Payable days | 95.12 | 85.35 |
| PER(x) | 12.39 | 11.94 |
| Price/Book(x) | 1.49 | 1.1 |
| Dividend Yield(%) | 1.13 | 1.41 |
| EV/Net Sales(x) | 0.91 | 0.78 |
| EV/Core EBITDA(x) | 6.82 | 6.84 |
| Net Sales Growth(%) | 0 | 1.52 |
| EBIT Growth(%) | 0 | -12.02 |
| PAT Growth(%) | 0 | -17.02 |
| EPS Growth(%) | 0 | -17.02 |
| Debt/Equity(x) | 0.03 | 0.05 |
| Current Ratio(x) | 1.99 | 1.92 |
| Quick Ratio(x) | 1.27 | 1.28 |
| Interest Cover(x) | 28.12 | 12.45 |
| Total Debt/Mcap(x) | 0.02 | 0.05 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 43.69 | 43.69 | 43.69 | 43.69 | 43.69 | 48.19 | 48.19 | 48.19 | 48.19 | 48.19 |
| FII | 3.03 | 3.14 | 2.5 | 2.42 | 2.37 | 2.43 | 3.54 | 2.34 | 2.18 | 1.41 |
| DII | 0.51 | 0.04 | 0.05 | 0.05 | 0.15 | 0.23 | 0.25 | 0.35 | 0.36 | 0.29 |
| Public | 52.77 | 53.13 | 53.77 | 53.84 | 53.79 | 49.15 | 48.03 | 49.13 | 49.27 | 50.11 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 | 2.83 | 2.83 | 2.83 | 2.83 | 2.83 |
| FII | 0.18 | 0.18 | 0.15 | 0.14 | 0.14 | 0.14 | 0.21 | 0.14 | 0.13 | 0.08 |
| DII | 0.03 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| Public | 3.1 | 3.12 | 3.16 | 3.16 | 3.16 | 2.89 | 2.82 | 2.88 | 2.89 | 2.94 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5.87 | 5.87 | 5.87 | 5.87 | 5.87 | 5.87 | 5.87 | 5.87 | 5.87 | 5.87 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
